Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16476941.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective alpha4beta2 nicotinic acetylcholine receptor agonist, in 77 individuals with early Parkinson disease. Lightheadedness was a common dosage-related adverse effect at higher dosages, leading to frequent dosage reduction, drug discontinuation, and eventual trial redesign. A maximally tolerated dosage of 10 mg daily was identified. No antiparkinsonian or cognitive-enhancing effects were demonstrated in this trial.
Medical subject headings
- Antiparkinson Agents
- Nicotinic Agonists
- Parkinson Disease
- Pyridines
- Pyrrolidines